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Anaphylactic	shock	is	a	sudden,	life-threatening	allergic	reaction	associated	with	severe	hypotension.	Plate-
let-activating	factor	(PAF)	is	implicated	in	the	cardiovascular	dysfunctions	occurring	in	various	shock	syn-
dromes,	including	anaphylaxis.	Excessive	production	of	the	vasodilator	NO	causes	inflammatory	hypotension	
and	shock,	and	it	is	generally	accepted	that	transcriptionally	regulated	inducible	iNOS	is	responsible	for	this.	
Nevertheless,	the	contribution	of	NO	to	PAF-induced	shock	or	anaphylactic	shock	is	still	ambiguous.	We	stud-
ied	PAF	and	anaphylactic	shock	in	conscious	mice.	Surprisingly,	hyperacute	PAF	shock	depended	entirely	on	
NO,	produced	not	by	inducible	iNOS,	but	by	constitutive	eNOS,	rapidly	activated	via	the	PI3K	pathway.	Solu-
ble	guanylate	cyclase	(sGC)	is	generally	regarded	as	the	principal	vasorelaxing	mediator	of	NO.	Nevertheless,	
although	methylene	blue	partially	prevented	PAF	shock,	neither	1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one	
(ODQ)	nor	sGCα1	deficiency	did.	Also,	in	2	different	models	of	active	systemic	anaphylaxis,	inhibition	of	NOS,	
PI3K,	or	Akt	or	eNOS	deficiency	provided	complete	protection.	In	contrast	to	the	unsubstantiated	paradigm	
that	only	excessive	iNOS-derived	NO	underlies	cardiovascular	collapse	in	shock,	our	data	strongly	support	the	
unexpected	concept	that	eNOS-derived	NO	is	the	principal	vasodilator	in	anaphylactic	shock	and	define	eNOS	
and/or	PI3K	or	Akt	as	new	potential	targets	for	treating	anaphylaxis.
Introduction
Anaphylaxis is an acute, severe, and potentially fatal systemic aller-
gic reaction that usually attacks the patient in the absence of a 
history of allergy. Causes of anaphylaxis include bee stings, medi-
cations, food, latex exposure, and exercise (1). Anaphylaxis is not 
as rare as generally believed and may affect as much as 1.2% to 15% 
of the US population (2). In addition, it is generally recognized 
that the prevalence of anaphylaxis is increasing significantly. Dur-
ing an anaphylactic reaction, serious cardiovascular or pulmonary 
dysfunction often leads to acute death, with severe hypotension 
as the cardinal clinical feature. Intravenous fluids and parenteral 
adrenaline administration are considered the only effective treat-
ment; unfortunately, severe cardiovascular collapse during ana-
phylaxis is often resistant to this treatment (1, 3).
Platelet-activating factor (PAF) is a biologically active phospho-
lipid. Although PAF was originally named after its ability to induce 
platelet aggregation, it stimulates a broad range of cell types and 
tissues by binding to a unique G protein–coupled 7 transmem-
brane receptor (PAF-R), activating a number of signaling pathways, 
including those that elevate intracellular calcium content and acti-
vate phospholipase A2 (PLA2) and PI3K (4). As PAF antagonists or 
PAF-R deficiency can prevent fatal anaphylaxis in animal models, 
PAF is thought to be a critical factor in the development of ana-
phylactic shock (5–9). In addition, PAF is known to contribute to 
hypotension and cardiac dysfunctions during hemorrhagic, trau-
matic, or septic shock (4). Nevertheless, the downstream molecular 
pathways beyond PAF-R triggering that direct its shock-inducing 
effect are still enigmatic. Both ROS and NO have been implicated 
in PAF shock, but whether their involvement is detrimental or ben-
eficial is still a matter of debate (10–12). However, most studies were 
performed in animals under general anesthesia, which influences 
NO-mediated effects and blood pressure considerably (13–15). 
Also, conflicting results in anaphylactic shock models have been 
reported with regard to the possible involvement of NO (16–19).
NO may be endogenously produced by the inducible iNOS or 
by the constitutively expressed isoforms eNOS and neuronal NOS 
(nNOS). While the latter are believed to produce low amounts of 
NO to execute physiological and/or antiinflammatory functions, 
the inflammation-associated expression of iNOS and the subse-
quent overproduction of NO are assumed to be responsible for 
the cardiovascular failure, morbidity, and mortality associated 
with (septic) shock (20, 21). In addition, it is generally accepted 
that NO-mediated activation of soluble guanylate cyclase (sGC) 
is the key mechanism in the regulation of vascular tone during 
(septic) shock (22, 23).
In this study, we aimed to unequivocally elucidate the involve-
ment and importance of NO, sGC, ROS, and PLA2 signaling in 
shock induced by intravenous PAF or anaphylaxis in conscious, 
nonanesthetized mice. We found that PAF-induced shock com-
pletely depended on PI3K signaling and on NO produced by 
the constitutive enzyme eNOS and not on NO produced by the 
inducible “inflammatory” iNOS. Downstream from NO, PAF 
shock appeared to be independent of sGC. Also, in 2 different 
models of active systemic anaphylaxis, absolute protection was 
obtained by inhibition of PI3K, Akt, or NOS or by eNOS deficien-
cy. Although it is generally accepted that excessive iNOS-derived 
NO underlies the cardiovascular collapse associated with shock, 
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our data provide compelling new evidence for a shock-inducing 
function of eNOS-derived NO.
Results
NO is critical for PAF-induced shock. Intravenous PAF injection in con-
scious mice elicits rapid shock and results in death within 20–30 
minutes (Figure 1A). When PAF engages its specific receptor, sev-
eral intracellular signaling events are triggered, including PLA2 
activation and superoxide production (4). Nevertheless, inhibition 
of these events by the PLA2 inhibitor aristolochic acid or the cell-
permeable superoxide dismutase mimetic tempol did	not provide 
any protection against PAF challenge (Figure 1A). In comparison, 
tempol or aristolochic acid provided complete protection against 
hyperacute shock induced by TNF in combination with the caspase 
inhibitor zVAD-fmk (24). As PAF may cause severe hypotension and 
iNOS induction (25), the vasorelaxant NO is generally assumed to 
be critically involved in PAF shock. Nonetheless, NOS inhibition 
cannot always preclude PAF-induced hypotension and sometimes 
even aggravates fatality (10–12). Since all of the aforementioned 
studies were performed in animals under general anesthesia, which 
is known to influence NO-mediated effects and blood pressure 
(13–15), we studied the effect of NOS inhibition on PAF hypoten-
sion and shock in conscious mice. We found that Nω-nitro-l-argi-
nine methyl ester (l-NAME) pretreatment completely protected 
against PAF lethality, implicating NO in a pivotal and detrimental 
function (Figure 1, A and B). Even when the PAF dose exceeded the 
LD100, l-NAME still provided absolute protection (not shown).
NO is thought to relax vascular smooth muscle cells by activa-
tion of sGC and subsequent cyclic GMP–dependent modification 
of several intracellular processes, including the phosphorylation 
of proteins of the contractile apparatus and of pumps or channels 
involved in modulating intracellular calcium and potassium levels 
(26). Moreover, recent studies reported that methylene blue (MB), 
an inhibitor of sGC activation, can reverse clinical anaphylactic 
shock induced by injected contrast media and prolong survival of 
rabbits in experimental anaphylaxis (27, 28). Nevertheless, MB (15 
mg/kg) did not prevent PAF shock to the same degree as l-NAME 
treatment, implying that sGC-independent NO activities are also 
involved (Figure 1, B and C). In comparison, MB provided 100% 
protection in a mouse model of TNF-induced shock as well as in a 
model of hyperacute shock induced by TNF in combination with 
the caspase inhibitor zVAD-fmk, as reported previously (24, 29). 
Also, lower doses of MB (5 and 10 mg/kg) still provided partial 
protection (data not shown). However, pretreatment with various 
doses (5, 10, 15, or 20 mg/kg) of another, more specific sGC inhibi-
tor, 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (ODQ) (23, 30), 
at different time points (4, 2, or 0.5 hours before challenge) did not 
protect (data not shown). In addition, sGCα1–/– mice (31) deficient 
for 1 of the 2 isoforms of the α subunit of the heterodimeric sGC 
enzyme were also not protected against PAF-induced shock (not 
shown). Together, these results suggest that, downstream from 
NO, sGC-independent events are most important.
To examine the hypotensive response to PAF, mean arterial 
blood pressure (MAP) was measured in unrestrained conscious 
mice using a catheter placed in the femoral artery. As documented 
before (8), intravenously administered PAF has an extremely fast 
and drastic hypotensive effect (Figure 2, A and C). However, when 
mice were pretreated with l-NAME, PAF caused only a transient 
and mild drop in blood pressure, followed by a very fast recovery 
in all but 1 of the mice (Figure 2B). All mice treated with PAF died 
within 13 minutes (Figure 2A) while only 1 of 5 animals pretreated 
with l-NAME died, after 44 minutes (Figure 2B). The MAP of the 4 
surviving l-NAME–treated mice 24 hours after PAF challenge was 
132 ± 18 mmHg. We therefore conclude that NO plays a dominant 
role in acute PAF-induced hypotension. Nevertheless, other vaso-
active mediators, such as histamine, serotonin, or leukotrienes, 
may also contribute in an NO-independent manner, albeit to a 
much smaller extent.
NO that causes PAF shock is produced by eNOS, activated via PI3K. To 
identify the NOS isoform involved, we used various NOS-deficient 
animals. Injection of PAF in iNOS-deficient mice caused a mortal-
ity that was similar to and as rapid as that observed in WT control 
animals, but age-matched eNOS-deficient animals were signifi-
cantly protected (Figure 3A), indicating an unexpected pivotal role 
for eNOS in PAF shock. Studies in vitro have shown that eNOS 
can be activated by direct serine phosphorylation, obviating the 
need for calcium and calmodulin binding and causing increased 
NO production (32, 33). This phosphorylation is mediated by the 
Figure 1
eNOS-derived NO is critical for PAF shock. C57BL/6 mice received 
various pretreatments and were challenged i.v. with 55 μg PAF; sur-
vival was monitored. (A) Pretreatment with vehicle, aristolochic acid 
(ArAc), tempol, or l-NAME (–4 hours). The number of mice is indicated 
between brackets. ***P < 0.0001; *P = 0.0201 compared with PAF. (B) 
Pretreatment with l-NAME 4, 2, or 1 hour before treatment with PAF. 
**P = 0.0165. (C) Pretreatment with MB 6, 4, 2, or 1 hour before PAF.
Downloaded August 14, 2014 from The Journal of Clinical Investigation. doi:10.1172/JCI25426.
research article
2246	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 116   Number 8   August 2006
PI3K/Akt pathway, which can be activated by receptor tyrosine 
kinases, G protein–coupled receptors, or mechanical forces such 
as shear stress. Pretreatment with wortmannin (WM), a specific 
inhibitor of PI3K, completely protected both WT and iNOS–/– mice 
(Figure 3A), demonstrating the critical importance of PI3K in PAF-
induced shock. In addition, Western blot analysis of WT kidney 
homogenates revealed specific Ser1177 eNOS phosphorylation 
after PAF challenge, which can be efficiently prevented by WM 
pretreatment (Figure 3B).
Anaphylactic shock depends on PI3K and eNOS-derived NO. To evalu-
ate the pathophysiological involvement of PI3K and eNOS-derived 
NO in shock in a clinically more relevant setting, we set up 2 dif-
ferent models of active systemic anaphylaxis, known to depend 
predominantly on PAF signaling (8, 9). Mice were first sensitized 
with BSA or OVA in the presence of adjuvants. A few weeks later, 
the animals were challenged intravenously with the same antigen. 
Soon after this challenge, mice developed severe hypothermia 
(demonstrated in Figure 4, B and D, for BSA-induced anaphy-
laxis) and rapidly succumbed to systemic shock reaction (Figure 
4A). However, when mice were pretreated with WM or l-NAME, 
hypothermia was transient and less severe (Figure 4B). While 75% 
of the control mice died, all 8 animals pretreated with WM or 
l-NAME survived the anaphylactic challenge (Figure 4A). Similar 
results were obtained in the OVA-induced anaphylaxis model (data 
not shown). Western blot analysis of WT kidney homogenates 
confirmed specific eNOS phosphorylation after BSA challenge in 
sensitized mice, prevented by WM pretreatment (Figure 4E). Next, 
we compared the 2 models of anaphylaxis in WT and eNOS-defi-
cient mice. Fatality in WT animals was 82% (9 of 11) for the BSA 
model and 92% (11 of 12) for the OVA model. In contrast, none 
of the eNOS-deficient mice died (Figure 4C; not shown for the 
OVA model). Moreover, for both anaphylaxis models, there was 
only a delayed, mild, and transient hypothermia in eNOS-deficient 
mice (Figure 4D). Neither BSA nor OVA had an effect on the tem-
perature or behavior of unsensitized mice (Figure 4, B and D; not 
shown for OVA). These results reveal an unexpected but pivotal 
role for PI3K and eNOS-derived NO in anaphylactic shock.
During anaphylaxis, vasodilation and hypotension are often 
associated with excessive vascular permeability and fluid extrava-
sation, resulting in a mixed distributive-hypovolemic shock. To 
assess vascular permeability, protein leakage was measured with 
the Evans blue (EB) technique. BSA or OVA in 1% EB was injected 
into the lateral tail vein, and subsequent EB extravasation into the 
ear tissue was analyzed (Figure 4F). In the BSA/BSA anaphylactic 
response, vascular permeability was significantly increased in WT 
mice but not in eNOS–/– animals (Figure 4F). Moreover, vascular 
leakage in BSA/BSA eNOS–/– mice was 2-fold lower than in WT 
mice (P < 0.01 by ANOVA). In OVA/OVA-induced shock, vascular 
permeability increased only in WT animals, and extravasation was 
again significantly lower in eNOS–/– OVA/OVA mice than in WT 
OVA/OVA animals (P < 0.001 by ANOVA) (not shown). In addition, 
pretreatment with WM or l-NAME clearly prevented EB extravasa-
tion in WT mice (P < 0.001, data not shown). Together, these data 
suggest the involvement of PI3K/eNOS in vascular leakage associ-
ated with anaphylaxis.
Once activated, PI3Ks generate phosphoinositide 3,4,5-trisphos-
phate (PIP3), leading to the recruitment and activation of Akt (pro-
tein kinase B), which then activates a range of downstream targets, 
Figure 2
MAP measurements during PAF shock. C57BL/6 mice were challenged i.v. with 55 μg PAF at t = 0. (A) Individual MAP of PAF-challenged mice. (B) 
Individual MAP of mice treated with l-NAME (100 mg/kg, i.v., –2 hours) and PAF. (C) Data points show the mean MAP ± SD of the plots shown in 
A and B. Error bars are plotted as vertical lines above and below the curves. The number of mice is indicated between brackets. ***P < 0.0001.
Figure 3
NO that causes PAF shock is produced by eNOS, activated via PI3K. 
(A) C57BL/6 (WT), iNOS–/–, or eNOS–/– mice were injected i.v. with 55 
μg PAF after pretreatment with vehicle or WM. Survival is presented 
as a combined Kaplan-Meier plot of 2 independent, representative 
experiments. The total number of mice is indicated between brackets. 
***P < 0.0001 compared with PAF in WT mice. (B) Western blot for 
phosphorylated eNOS (p-eNOS) in kidney homogenates of individual 
mice 7 or 15 minutes after PAF injection. Where indicated, mice were 
pretreated with WM.
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including eNOS. Akt exists as 3 isoforms (Akt1, Akt2, and Akt3) 
that share extensive structural similarity and that may have unique 
as well as common functions within the cell. To corroborate the 
importance of the PI3K/Akt pathway in anaphylaxis, we treated 
OVA-sensitized mice with perifosine, a lipid-based inhibitor of Akt 
for which phase I and II clinical trials are being conducted (34, 35). 
As depicted in Figure 5, A and B, all mice pretreated with perifosine 
suffered much less from hypothermia and survived the otherwise 
100% lethal OVA challenge. For all Akt isoforms, knockout mice 
have been created (36–38). As Akt1 is the predominant Akt isoform 
in endothelial cells (39), we also studied anaphylactic shock in 
Akt1-deficient mice. However, Akt1–/– ani-
mals were not protected, except for a minor 
(but significant) delay in mortality, as com-
pared with WT mice (Figure 5C).
To examine the effect of NOS deficiency 
on anaphylaxis-induced hypotension, MAP 
was measured in unrestrained conscious 
mice 3 days after surgical catheter inser-
tion into the right femoral artery. In ani-
mals previously sensitized by BSA, intra-
venous BSA challenge had an immediate 
precipitous hypotensive effect, resulting 
in mortality, regardless of the challenging 
dose of BSA used (2, 1, or 0.1 mg) (Figure 
6A). When mice were challenged with 2 mg 
BSA, pretreatment with l-NAME only pro-
longed survival: l-NAME mice died 40–81 
minutes after challenge while all control 
animals were dead within 20 minutes. 
However, when 0.1 mg BSA was used as a 
challenge, the BSA challenge in l-NAME 
pretreated mice caused only a transient 
drop in blood pressure, followed by a 
very fast recovery in all but 1 mouse (Fig-
ure 6B). All mice treated with 0.1 mg BSA 
died within 15 minutes (Figure 6, A and C) 
while only 1 of 4 animals pretreated with 
l-NAME died, after 72 minutes (Figure 6B).
Discussion
NO has been shown to play a primary 
and harmful role in (septic) shock, caus-
ing progressive refractory hypotension 
and ultimately leading to multiple organ 
dysfunction and death. Constitutive NOS 
enzymes (eNOS and nNOS) are believed to 
produce low amounts of NO essential for 
various physiological and/or antiinflam-
matory events while higher amounts of 
NO are produced by inducible iNOS dur-
ing inflammation (20, 21). It is generally 
accepted that during inflammation and 
shock, cardiovascular collapse is initiated 
and mediated by excessive production of 
NO due to the transcriptional induction 
of the inducible “inflammatory” isoform 
iNOS, a process that requires hours rather 
than minutes. Downstream, sGC is regard-
ed as the principal vasorelaxing mediator 
of NO in the cardiovascular system (22, 23, 26).
As PAF can participate in the induction of iNOS (25), induced 
NO is assumed to mediate PAF-induced hypotension and shock. 
While some investigators have reported that NOS inhibitors can 
prevent PAF-induced hypotension (40, 41), others reported that 
it cannot (11, 12). However, all of these studies were performed in 
animals under general anesthesia, known to influence NO-medi-
ated effects and blood pressure changes considerably (13–15). In 
addition, NOS inhibitors have also been reported to exacerbate 
PAF shock, including enhanced pulmonary hypertension (11), 
aggravated alveolar permeability (12), and even an increase in 
Figure 4
BSA anaphylactic shock in WT and eNOS–/– mice. (A) Survival plot of C57BL/6 mice sensitized 
with BSA, treated with vehicle (controls), l-NAME, or WM, and finally challenged with BSA in 
EB. The number of mice in each experimental group is shown in parentheses. **P = 0.0022. (B) 
Temperature plot (mean ± SD) of mice sensitized by BSA or PBS and challenged 15 days later 
with BSA in EB (BSA + EB) or EB alone. The total number of mice is shown in parentheses; 
numbers beneath time points indicate the number of mice still alive at the indicated times. (C) 
Survival plot of WT and eNOS–/– mice sensitized with BSA and challenged with BSA in EB. Total 
number of mice is shown in parentheses. ***P = 0.0007. (D) Temperature plot (mean ± SD) of 
mice sensitized by BSA or PBS and challenged with BSA in EB or EB alone. The total number of 
mice is shown in parentheses, numbers above the time points indicate the number of mice still 
alive at the indicated times. (E) Western blot for p-eNOS in kidney homogenates of individual, 
BSA-sensitized mice 12 minutes after BSA challenge. Where indicated, mice had been pre-
treated with WM. (F) Vascular leakage assayed by EB extravasation into ear tissues. Inner ear 
rims were removed 90 minutes after i.v. challenge with BSA in EB or EB only and subsequently 
extracted in formamide. Plots show mean OD620 ± SD. #P < 0.001; ##P < 0.01.
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mortality of experimental animals (10, 12). In vitro, PAF stimu-
lates leukocyte superoxide production, chemotaxis, and adhesion 
(42). Although it has been suggested that some biological activi-
ties of PAF are mediated by ROS, antioxidants such as butylated 
hydroxytoluene, vitamin E, or N-acetylcysteine failed to inhibit 
PAF-induced mortality, disseminated intravascular coagulation, 
or pulmonary edema (43, 44). Furthermore, the exact role of NO 
in various anaphylactic shock models also remains unclear, with 
reports ranging from l-NAME–induced reduction of mortality 
(16) to reduced survival (17, 19).
In the present study, we set out to unequivocally elucidate the 
involvement and importance of NO, sGC, ROS, and PLA2 sig-
naling in shock induced by intravenous PAF in conscious, non-
anesthetized mice. To validate the results we obtained in the PAF-
induced shock model, we also used 2 different models of active 
murine anaphylactic shock.
We found that PAF-induced mortality was not influenced by anti-
oxidant treatment or PLA2 inhibition. Intravenous PAF injection in 
conscious mice elicited a very acute and drastic drop in blood pres-
sure, resulting in death within only 20–30 minutes. As iNOS activa-
tion depends on de novo synthesis of both RNA and protein, sev-
eral hours are required for its full activation. Surprisingly, however, 
NOS inhibition by l-NAME prevented PAF-induced hypotension 
and provided complete protection, even against PAF doses exceed-
ing the LD100. Moreover, whereas PAF injection in iNOS-deficient 
mice caused equally rapid mortality, eNOS-deficient animals were 
protected, indicating an unexpected pivotal role for eNOS-derived 
NO in PAF shock. Inhibitors of sGC protected either partially (MB) 
or not at all (ODQ), and sGCα1–/– and WT mice suffered equally 
from PAF-induced shock. Catalytically active sGC heterodimers are 
composed of an α1 or α2 subunit combined with a β1 subunit. Of 
interest, direct pharmacological sGC activation did not cause vaso-
relaxation or hypotension in sGCα1–/– mice, indicating that sGC-
dependent cardiovascular events predominantly rely on sGCα1 
(31). Our results therefore imply that, downstream from NO, sGC-
independent events are most important during PAF shock.
Traditionally, eNOS has been considered a constitutively 
expressed enzyme regulated by calcium and calmodulin. However, 
Figure 5
OVA anaphylactic shock in WT and Akt1–/– mice. (A) Survival plot of 
C57BL/6 mice sensitized with OVA, pretreated with vehicle (controls) 
or perifosine, and challenged 19 days later with OVA in 1% EB. The 
total number of mice in each experimental group is shown in parenthe-
ses. ***P = 0.0002. (B) Temperature plot (mean ± SD) of mice sensi-
tized by OVA and challenged 19 days later with OVA in 1% EB. The 
total number of mice is shown in parentheses, and numbers below the 
time points indicate the number of mice still alive at the indicated times. 
(C) Survival plot of WT and Akt1–/– mice, sensitized with OVA and chal-
lenged 20 days later with OVA in 1% EB. The total number of mice is 
shown in brackets in the legend. **P = 0.0043.
Figure 6
MAP measurements during anaphylactic shock. BSA-sensitized C57BL/6 mice were challenged i.v. with BSA at t = 0. (A) Individual MAP of mice 
challenged with 2, 1, or 0.1 mg BSA. (B) Individual MAP of mice pretreated with l-NAME (200 mg/kg, i.v.; –2 hours) and 0.1 mg BSA (t = 0). (C) 
Data points show the mean MAP ± SD of the 0.1 mg BSA plots shown in A and B. Error bars are plotted as vertical lines above and below the 
curves. Number of mice is indicated in parentheses. ***P < 0.0001.
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phosphorylation of a C terminal serine residue through the PI3K/
Akt pathway activates the eNOS enzyme at resting calcium levels 
and/or increases its activity (32, 33, 45). Interestingly, PI3K/Akt-
dependent eNOS phosphorylation and ensuing NO production 
occur much faster than iNOS-dependent NO production, gener-
ally reaching a maximum within only 10 to 15 minutes of stimula-
tion (32, 46, 47). In our study, pretreatment with WM, a specific 
PI3K inhibitor, prevented PAF-induced eNOS Ser1177 phosphory-
lation and efficiently protected both WT and iNOS-deficient mice 
from PAF shock. Hence, we conclude that there is a critical role for 
PI3K in the rapid activation of eNOS during PAF-induced shock.
To assess the pathophysiological role of PI3K/Akt and eNOS-
derived NO in a clinically more relevant shock setting, we tested 
the effects of WM, perifosine, l-NAME, and eNOS or Akt1 defi-
ciency in 2 different active and acute systemic anaphylaxis models. 
The experiments revealed a critical role for PI3K/Akt and eNOS-
derived NO in anaphylactic shock. Following pretreatment with 
WM, perifosine, or l-NAME or in conditions of eNOS deficiency, 
anaphylaxis-induced hypothermia was mild and transient, vascu-
lar permeability was significantly lower, and no deaths occurred 
at all, indicating that PI3K/Akt-activated eNOS-derived NO is the 
most important vasodilator in anaphylactic shock.
Understanding the requirement of Akt in mammals is com-
plicated by the existence of 3 highly conserved isoforms, Akt1, 
Akt2, and Akt3. Akt1-deficient mice show impaired overall 
growth, Akt2 knockout mice are insulin intolerant, demonstrat-
ing a diabetes-like syndrome, and mice lacking Akt3, which has 
more limited distribution, display a selective reduction in brain 
size (36–38, 48). Despite the protection obtained by Akt inhibi-
tion, Akt1–/– mice were not protected against anaphylactic shock, 
except for a minor delay in mortality. However, the viability of 
adult mice lacking each individual Akt isoform suggests that 
there is functional redundancy among these proteins. Interest-
ingly, mice lacking both Akt1 and Akt2 die shortly after birth (49). 
In addition, endothelial cells of Akt1-deficient mice still show 
robust Akt levels and increased eNOS phosphorylation following 
VEGF treatment, which clearly provides evidence of the presence 
of compensatory mechanisms (39). This redundancy may explain 
why the Akt inhibitor perifosine is much more efficient than Akt1 
deficiency in preventing anaphylactic shock.
Historically, the constitutively expressed eNOS enzyme was 
never seriously implicated as a detrimental mediator of inflam-
mation. On the contrary, eNOS-derived NO was generally consid-
ered to exercise a rather antiinflammatory role (20). Nevertheless, 
the early activation of eNOS was already linked to an early, tran-
sient vascular hyporeactivity during both endotoxic and hemor-
rhagic shock more than a decade ago (50, 51). Although eNOS was 
originally believed to be constitutively expressed and modulated 
exclusively via changes in intracellular calcium concentration, it 
has now become clear that eNOS can be induced several-fold by 
multiple stimuli (such as shear stress, estrogen, and VEGF) and 
posttranslationally activated through protein phosphorylation or 
protein-protein interactions (45, 52). Moreover, eNOS deficiency 
or eNOS inactivation efficiently prevents the acute local inflam-
matory response induced by subplantar carrageenan injection (53, 
54). Very recently, an important function for eNOS in facilitat-
ing iNOS expression and hypotension in endotoxemia was found, 
demonstrating a regulatory role for eNOS-derived NO in the gene 
expression of inflammatory mediators such as iNOS (55, 56). Our 
present study reveals what we believe is a new and surprising con-
cept that eNOS-derived NO is the principal vasodilator in PAF-
induced and anaphylactic shock, thereby strongly supporting the 
emerging belief in a possible detrimental role for eNOS in regulat-
ing inflammation and/or vascular function during shock.
In addition, MAP measurements in anaphylactic shock demon-
strated that the abrupt and precipitous drop in blood pressure, 
which happens immediately after the challenge and lasts only a 
couple of minutes, is clearly NOS/NO-independent. This may be 
attributed to the rapid release of preformed vasoactive mediators, 
such as histamine and/or serotonin. However, following this ini-
tial dramatic blood pressure drop (of ± 80 mmHg), l-NAME–pre-
treated mice quickly recovered and eventually survived while con-
trol animals suffered a continued steep drop in blood pressure, 
leading to abrupt mortality. These data clearly demonstrate that 
eNOS-dependent vasorelaxation is key to the sustained hypoten-
sion causing shock and mortality during anaphylaxis.
Up until lately, very little was known about the role of PI3K in 
the cardiovascular system. Recently, the PAF/PI3K/eNOS path-
way was reported to exert a potent negative inotropic effect on the 
heart and to be an important cause of myocardial dysfunction fol-
lowing ischemia/reperfusion (57, 58). Our data provide important 
additional information on a similar detrimental effect of the PAF/
PI3K/eNOS pathway with respect to shock. In addition, we clearly 
demonstrate that anaphylactic shock in conscious mice is crucially 
orchestrated by PI3K/Akt and eNOS-derived NO. Although cyclic 
GMP/protein kinase G–dependent phosphorylation of the con-
tractile machinery and calcium-regulating proteins is generally 
assumed to be the major mechanism by which NO causes patho-
logical vascular smooth muscle relaxation, our results suggest that 
sGC-independent actions of NO may contribute significantly to its 
shock-inducing effect in vivo. As a general conclusion, we propose 
that selective targeting of eNOS and/or PI3K or Akt may provide 
new tools for the treatment of anaphylactic shock.
Methods
Mice. Female C57BL/6 mice were purchased from Elevage Janvier and Akt1–/– 
mice from Jackson Laboratory, where we also obtained iNOS-deficient (59) 
and eNOS-deficient (60) mice on a C57BL/6 background to breed in our 
facilities. The sGCα1–/– mice were generated as reported (31), and litter-
mates were used as controls. Mice were housed in temperature-controlled, 
air-conditioned facilities with 14-hour light/10-hour dark cycles and food 
and water ad libitum. All data were collected using mice 8–12 weeks of age. 
All experiments were approved by and performed according to the guide-
lines of the animal ethics committees of Ghent University, Belgium, and 
Maastricht University, The Netherlands.
Cytokines, reagents, injections, body temperature, and MAP measurements. PAF 
(1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine; Sigma-Aldrich) was 
diluted in 200 μl endotoxin-free PBS supplemented with 0.25% BSA and 
injected i.v. Mortality was scored up to 7 days after challenge. The NOS 
inhibitor l-NAME was purchased from Novabiochem and injected i.v. at 
a dose of 100 mg/kg. Tempol (Sigma-Aldrich) was injected i.p. at 6 mg/
mouse 1 hour before PAF. Aristolochic acid (Sigma-Aldrich) was admin-
istered s.c. in 50 μl DMSO 1.5 hours before PAF at 120 μg/mouse. MB in 
glucose solution suitable for i.v. injection (MB; Sterop) was used at a dose 
of 15 mg/kg unless otherwise stated. All of these treatments were based 
on the protective effects observed in our previous studies (24, 29). ODQ 
(Tocris Bioscience) was used i.p. in 50 μl DMSO at 20, 15, 10, or 5 mg/kg. 
WM (Sigma-Aldrich, 30 μg/mouse in 1.5% DMSO) was given i.p. 1.3 
hours before the PAF challenge. Perifosine (octadecylphosphopiperidine; 
Keryx Biopharmaceuticals) was injected s.c. (1 mg/100 μl PBS/mouse) for 
Downloaded August 14, 2014 from The Journal of Clinical Investigation. doi:10.1172/JCI25426.
research article
2250	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 116   Number 8   August 2006
4 consecutive days, the last treatment being 2 hours before challenge. Rec-
tal body temperature was recorded with an electronic thermometer (model 
2001; Comark). Blood pressure and heart rate were measured continuously 
in conscious, permanently catheterized C57BL/6 mice, as described (24, 
29). Briefly, a heat-stretched piece of polyethylene tubing was inserted into 
the right femoral artery. Similarly, a catheter was placed in the jugular vein 
for drug injections. After surgery, animals received Ringer solution (Baxter 
BV) and analgesic and were kept at 30°C to improve recovery. Experiments 
were performed 3 days after surgery, at which time the catheter was con-
nected to a low-volume pressure transducer to record MAP and HR con-
tinuously throughout the study. The setup was allowed to stabilize for at 
least 40 minutes before the experiment was started.
Active systemic anaphylaxis models. Two different sensitization models were 
used: (a) Mice were given a single i.p. injection of 1 mg BSA (Sigma-Aldrich) 
mixed with 300 ng pertussis toxin (Sigma-Aldrich). Anaphylaxis was elic-
ited 15 days later by i.v. injection of 2 mg of BSA. In the hemodynamic 
studies, the dose of BSA had to be lowered from 2 to 0.1 mg because the 
surgical procedures led to a sensitization to the BSA challenge. (b) Mice 
were sensitized by i.p. injection of 100 μg OVA (Sigma-Aldrich), aluminum 
hydroxide (Sigma-Aldrich, 1 mg) and pertussis toxin (300 ng). Mice were 
challenged 19–20 days later by i.v. injection of 150 μg OVA. When appro-
priate, mice were pretreated with l-NAME (i.v., –2.0 hours), WM (i.p., –1.3 
hours), or perifosine (s.c.). Sensitizing i.p. injections were given in 0.5 ml of 
endotoxin-free PBS. To permit analysis of vascular permeability, challenges 
were injected into the lateral tail vein in 0.2 ml of 1% EB in endotoxin-free 
PBS, and ear biopsies were taken 90 minutes later. Control mice were chal-
lenged with EB only. As long as vascular permeability is unaffected, EB 
remains confined to the intravascular space. To quantify vascular leakage, 
ear biopsies were incubated in 0.3 ml formamide at 60°C for 4 days to 
extract EB from the tissue; absorption was measured at 620 nm.
Western blot analysis. Mice were pretreated with WM or vehicle and 1.3 
hours later challenged with a lethal dose of PAF, BSA, or OVA. They were 
euthanized by cervical dislocation at the indicated time. Organs were dis-
sected, snap-frozen in liquid nitrogen, and homogenized in a lysis buffer 
suitable for detecting phosphorylated proteins containing 50 mM HEPES, 
5 mM EDTA, 250 mM NaCl, 0.1% Nonidet P-40, 0.15 μM aprotinin, 2.1 μM 
leupeptin, 1 mM Pefabloc, 25 mM β-glycerolphosphate, 0.2 mM sodium 
vanadate, and 10 mM sodium fluoride. After centrifugation of cell debris, 
protein concentrations were determined (Bio-Rad), and 20 mg were used for 
immunoprecipitation with mouse anti-eNOS (BD Biosciences — Pharmin-
gen). Purified eNOS was resolved in a 4–12% Bis-Tris gel (Invitrogen) and 
transferred to nitrocellulose (Schleicher & Schuell BioScience). Filters were 
blocked for 1 hour at room temperature in TBS containing 0.1% Tween 20 
(TBS/T) supplemented with 5% milk powder. The filters were incubated 
overnight at 4°C with a mAb against phosphorylated eNOS (Ser1177) (Cell 
Signaling Technology) in TBS/T with 5% BSA, washed 5 times with TBS/T, 
and incubated for 1 hour at room temperature with a goat anti-rabbit 
IgG conjugated with horseradish peroxidase (Cell Signaling Technology). 
Afterwards, 5 washes with TBS/T preceded development with the Chemi-
luminescent Reagent Plus (ECL) detection reagent (PerkinElmer).
Statistics. Statistics were performed using GraphPad Prism version 4.0 
(GraphPad Software; log-rank test for comparison of survival curves, 
c2 test to compare total mortality percentages, unpaired 2-tailed Student’s 
t test to compare mean MAP data, and 1-way ANOVA with Bonferroni’s 
multiple comparison test for EB extravasation data).
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